Citron Research says it has a 'smoking gun' on Valeant Pharma (VRX)

Valeant Pharma (VRX) Shares Active Ahead of Monday's Conference Call

October 23, 2015 3:53 PM EDT

Embattled specialty pharmaceutical company Valeant Pharma (NYSE: VRX) was in focus heading into the close of trading Friday, as it gets set to address investors during a critical conference call on Monday morning. On the call, management must untangle its relationship with... More

Valeant Pharma (VRX) Used Backdoor Approach to Gain Pharmacy Stake in California - ProPublica

October 22, 2015 5:48 PM EDT

Valeant Pharma (NYSE: VRX) is on watch following a new article from ProPublica which highlights documents that raise new questions about the company's pharmacy relationships in California.

From the... More

Deutsche Bank 'Remains Cautious' on Valeant (VRX); Analyst Maintains Hold Rating

October 22, 2015 9:37 AM EDT

Deutsche Bank maintained a Hold rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $204. Analyst Gregg Gilbert said he remains cautious on the stock given uncertainties related to the drug pricing, its specialty pharmacy distribution model, and related government inquiries.

Gilbert explained, "VRX shares have been under significant pressure, most recently following allegations related to its specialty pharmacy distribution model. While it is difficult to predict how more conservative pricing behavior and other potential changes could affect revenue growth, we thought it would be helpful to look at... More

Valeant Pharma (VRX) Taps Lows Below $90/Share

October 21, 2015 1:24 PM EDT

Valeant Pharma (NYSE: VRX) declined 38% to session lows at around 1:20 pm on Tuesday, briefly traded under $90 per share. The massive slide follows Citron Research's fraud report earlier. So far the company hasn't responded, which might be viewed as a negative by some investors.

... More

Icahn Wishes He Was Short Valeant (VRX) Stock - CNBC

October 21, 2015 12:42 PM EDT

Carl Icahn said Valeant Pharma (NYSE: VRX) is 'prime example' of inversion, according to an interview on CNBC today. Icahn also noted that he doesn't have a long position in the stock, but wishes he had a short position.

... More

Mizuho Weighs in on Panic in Specialty Pharmaceuticals Sector (VRX) (AGN) (ENDP) (SCMP) (JAZZ) (MNK)

October 21, 2015 12:39 PM EDT

Mizuho Securities analyst Irina Koffler offered some comments on the specialty pharmaceutical sector give the panic following reports of fraud at Valeant Pharma (NYSE: VRX).

Koffler key points are highlighted below:

Our Neutral thesis on VRX is intact: We cannot verify or dispute the allegations made by Citron Research or SIRF about Valeant's Philidor pharmacy. That said, it almost doesn't matter as the stock appears broken and management will now have to defend the story rather than focus on its organic growth and M&A. We initially used a 14% WACC... More